{"filing":{"accession_number":"0001213900-26-097851","cik":"0001553643","ticker":"RLMD","company_name":"RELMADA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-03","primary_document":"ea0304768-8k_relmada.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/ea0304768-8k_relmada.htm"},"events":[{"id":31813,"run_id":29212,"accession_number":"0001213900-26-097851","anchor_item_number":"8.01","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026. This is a clear departure of a named executive officer from the company. The disclosure focuses on the termination of employment rather than appointment or compensation arrangements, making exec_departure the appropriate classification.","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34810,"accession_number":"0001213900-26-097851","item_number":"8.01","item_title":"Other Events.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026. This is a clear departure of a named executive officer from the company. The disclosure focuses on the termination of employment rather than appointment or compensation arrangements, making exec_departure the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:02:13.920993+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34810,"accession_number":"0001213900-26-097851","item_number":"8.01","item_title":"Other Events.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026. This is a clear departure of a named executive officer from the company. The disclosure focuses on the termination of employment rather than appointment or compensation arrangements, making exec_departure the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:02:13.920993+00:00","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-09-08"}]}